NovoCure Ltd (NASDAQ:NVCR) has a beta value of 0.70 and has seen 2.48 million shares traded in the last trading session. The company, currently valued at $1.92B, closed the last trade at $17.78 per share which meant it gained $1.72 on the day or 10.71% during that session. The NVCR stock price is -39.15% off its 52-week high price of $24.74 and 38.86% above the 52-week low of $10.87. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.95 million shares traded. The 3-month trading volume is 995.37K shares.
The consensus among analysts is that NovoCure Ltd (NVCR) is Hold stock at the moment, with a recommendation rating of 2.14. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 5 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.33.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ:NVCR) trade information
Sporting 10.71% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NVCR stock price touched $17.78 or saw a rise of 8.02%. Year-to-date, NovoCure Ltd shares have moved 19.09%, while the 5-day performance has seen it change 21.28%. Over the past 30 days, the shares of NovoCure Ltd (NASDAQ:NVCR) have changed -1.00%. Short interest in the company has seen 5.49 million shares shorted with days to cover at 5.67.
Wall Street analysts have a consensus price target for the stock at $35, which means that the shares’ value could jump 49.2% from current levels. The projected low price target is $14.5 while the price target rests at a high of $200.0. In that case, then, we find that the current price level is -1024.86% off the targeted high while a plunge would see the stock lose 18.45% from current levels.
NovoCure Ltd (NVCR) estimates and forecasts
Figures show that NovoCure Ltd shares have outperformed across the wider relevant industry. The company’s shares have gained 42.70% over the past 6 months, with this year growth rate of 31.28%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be 13.90%.
7 analysts offering their estimates for the company have set an average revenue estimate of 143.85M for the current quarter. 7 have an estimated revenue figure of 147.69M for the next ending quarter. Year-ago sales stood 127.32M and 133.78M respectively for this quarter and the next, and analysts expect sales will grow by 13.00% for the current quarter and 13.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -22.97% over the past 5 years.
NVCR Dividends
NovoCure Ltd is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
Insiders own 9.23% of the company shares, while shares held by institutions stand at 86.56% with a share float percentage of 95.36%. Investors are also buoyed by the number of investors in a company, with NovoCure Ltd having a total of 331.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 16.14 million shares worth more than $276.51 million. As of 2024-06-30, FMR LLC held 15.0482% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 12.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $207.83 million and represent 11.3106% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Smallcap World Fund . As of Aug 31, 2024 , the former fund manager holds about 4.91% shares in the company for having 5.31 shares of worth $94.41 million while later fund manager owns 4.52 shares of worth $80.43 million as of Jun 30, 2024 , which makes it owner of about 4.18% of company’s outstanding stock.
